21% of AML patients went to stem cell transplant
Ten patients advanced to transplant after treatment with mipletamig, a 30-fold increase over historical VEN+AZA rates, supporting further clinical development.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed